A rare disease is any condition that affects fewer than 200,000 people in the United States. That threshold comes from the Orphan Drug Act, a 1983 law Congress passed to encourage drug companies to develop treatments for small patient populations. In the European Union, the cutoff is slightly different: a disease is considered rare if fewer than 5 in 10,000 people have it. Despite the word “rare,” these conditions collectively affect a staggering number of people, with an estimated 263 to 446 million individuals living with a rare disease worldwide at any given time.
How the Numbers Break Down
Researchers have identified more than 10,000 distinct rare diseases. That figure comes from combining data across the major international disease databases, and it’s higher than the 7,000 often cited by advocacy groups and government agencies. The list keeps growing as genetic testing improves and clinicians recognize new conditions.
About 80% of rare diseases have a genetic origin. The rest can be caused by infections, autoimmune dysfunction, environmental exposures, or unknown factors. Because so many are genetic, rare diseases disproportionately affect children. Roughly 75% of all rare disease cases show up in childhood, and about 30% of affected children do not survive past age five.
Rare vs. Ultra-Rare
Within the rare disease category, there’s another tier. Conditions affecting fewer than 1 in 50,000 people are sometimes classified as ultra-rare. Some researchers have even proposed a category called “hyper-rare” for diseases affecting fewer than 1 in 100 million, conditions so infrequent that no living person on the planet may have them at any given moment. These distinctions matter because they influence how much research funding a disease attracts and how aggressively pharmaceutical companies pursue treatments.
The Diagnostic Journey
One of the defining experiences of living with a rare disease is the long road to getting a correct diagnosis. On average, patients wait about 7 years from their first symptoms to the start of a specialized diagnostic workup. For adults, that average stretches to over 10 years. During that time, patients typically see around 7 different specialists, compared to about 4 for people with more common conditions.
This delay happens for straightforward reasons. Many rare diseases share symptoms with common ones, so doctors often pursue the most likely explanations first. A condition that only a handful of specialists in the country have seen before is easy to miss, especially in a general practice setting. Genetic testing has shortened this timeline for some patients, but the gap remains wide.
Treatment Is the Exception, Not the Rule
Only about 5% of rare diseases have an FDA-approved treatment. Over the full 40-year history of the Orphan Drug Act, just 4 to 6% of rare conditions have gained at least one approved therapy. That leaves the vast majority of patients managing symptoms without a targeted drug.
The pace is picking up, though. In 2024, 26 of the FDA’s 50 new drug approvals (52%) carried an orphan drug designation, meaning they were developed specifically for rare conditions. Two of those treated diseases with no previously approved option at all. That’s a meaningful shift from the early years of the Orphan Drug Act, when very few companies saw a financial case for pursuing small-market drugs.
Why “Rare” Doesn’t Mean “Small”
Each individual rare disease affects a small number of people, but taken together, rare diseases are a major public health issue. The estimated global prevalence of 3.5 to 5.9% of the population means rare diseases collectively affect roughly as many people as diabetes or asthma. That figure is conservative, based on data from about two-thirds of known rare conditions and excluding rare cancers, infectious diseases, and poisonings.
This is why rare disease advocacy has gained so much political and scientific traction over the past two decades. When 300 million or more people worldwide share the experience of having a condition most doctors have never encountered, the “rare” label starts to feel misleading. The diseases are individually uncommon, but the burden they place on patients, families, and healthcare systems is anything but.